-

12:35:47 PM

MBRX Stock News

MBRX - Moleculin Biotech Inc

05/19/22 8:05 AM

Nasdaq : MBRX

conferences

Moleculin to Present at the H.C. Wainwright Global Investment Conference

Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief

RHEA-AI

neutral

05/12/22 8:35 AM

Nasdaq : MBRX

earnings

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

– Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies –– Multiple key clinical and regulatory milestones expected throughout 2022 –– Company has sufficient capital to fund operations into 2024 –HOUSTON , May 12, 2022

RHEA-AI

positive

05/10/22 8:35 AM

Nasdaq : MBRX

clinical trialcovid-19

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a

RHEA-AI

neutral

05/05/22 8:15 AM

Nasdaq : MBRX

clinical trial

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

– Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine– Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine combined compared to Annamycin as a single agent

RHEA-AI

positive

05/04/22 8:15 AM

Nasdaq : MBRX

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomasCompany continues to advance clinical development across priority development pipeline with

RHEA-AI

very positive

04/21/22 8:47 AM

Nasdaq : MBRX

clinical trial

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with

RHEA-AI

neutral

04/14/22 8:05 AM

Nasdaq : MBRX

Moleculin Announces Corporate Rebranding and Launch of New Website

Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the

RHEA-AI

positive

04/11/22 7:05 AM

Nasdaq : MBRX

/C O R R E C T I O N -- Moleculin Biotech, Inc./

In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised by the company that the second paragraph following the details section, third sentence, should

RHEA-AI

positive

04/08/22 1:05 PM

Nasdaq : MBRX

Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting

RHEA-AI

positive

03/25/22 7:05 AM

Nasdaq : MBRX

earnings

Moleculin Reports Full Year Financial Results and Provides Programs Update

– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine –– Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute Myeloid Leukemia (AML) and metastases of Soft Tissue

RHEA-AI

positive

1 2 3 4 5 6 7 8 Next

MBRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.moleculin.com
Security nameMoleculin Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees13
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address5300 Memorial Dr Ste 950
StateTexas
CityHouston
Zip77007-8274
CountryUnited States
Phone17133005160

About Moleculin Biotech Inc

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.